WEBINAR: Considerations for Remote Assessment in NASH Studies

Register Now

Non-alcoholic fatty liver disease is the most common chronic liver condition in Western populations and is fueled by obesity and type 2 diabetes epidemics. NASH prevalence is expected to increase by 63% between 2015 and 2030 and is expected to become the leading cause of liver transplantation in the United States between 2020-2025.

With this steady rate of growth, conducting NASH studies remotely and the ability to engage and assess patients, while maintaining high data quality is increasingly important.

Join Dr. Nadege Gunn and Marlen Rattiner in our upcoming webinar to learn more.